Arrowhead Pharmaceuticals... (ARWR)
| Bid | 20.25 |
| Market Cap | 2.95B |
| Revenue (ttm) | 596.57M |
| Net Income (ttm) | -148.42M |
| EPS (ttm) | -1.2 |
| PE Ratio (ttm) | -17.77 |
| Forward PE | -6.18 |
| Analyst | Buy |
| Ask | 21.8 |
| Volume | 2,429,736 |
| Avg. Volume (20D) | 1,970,524 |
| Open | 20.88 |
| Previous Close | 20.75 |
| Day's Range | 20.72 - 21.70 |
| 52-Week Range | 9.57 - 27.34 |
| Beta | 0.95 |
About ARWR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D....
2 weeks ago · fool.com
Arrowhead (ARWR) Q3 Revenue Drops 41%Arrowhead (ARWR) Q3 Revenue Drops 41%
2 weeks ago · businesswire.com
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter ResultsPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is host...
1 month ago · businesswire.com
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter ResultsPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discus...
